[1]周磊 张晓红 汪永生 程鹏 李胜 周跟东 杜政勋.H2FPEF评分N末端对射血分数保留心力衰竭患者预后评估价值的探讨[J].心血管病学进展,2020,(6):665.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2020.06.025]
　ZHOU Lei,ZHANG Xiaohong,WANG Yongsheng,et al.The Predictive Value of H2FPEF Score and NT-proBNP in Heart Failure with Preserved Ejection Fraction Patients[J].Advances in Cardiovascular Diseases,2020,(6):665.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2020.06.025]
点击复制

H2FPEF评分N末端对射血分数保留心力衰竭患者预后评估价值的探讨()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年6期
页码:
665
栏目:
论著
出版日期:
2020-06-25

文章信息/Info

Title:
The Predictive Value of H2FPEF Score and NT-proBNP in Heart Failure with Preserved Ejection Fraction Patients
作者:
周磊1 张晓红 汪永生1 程鹏1 李胜1 周跟东1 杜政勋1
(安徽医科大学第三附属医院 合肥市第一人民医院心内科合肥 230061)
Author(s):
ZHOU Lei;  ZHANG Xiaohong;  WANG Yongsheng;  CHENG peng; LI Sheng;  ZHOU Gendong;  DU Zhengxun
(Department of Cardiology The Third Affiliated Hospital of Anhui Medical University ,The First People’s Hospital of HeFei,,Hefei230061,Anhui
关键词:
心力衰竭; 射血分数保留心力衰竭; NT-proBNP
Keywords:
heart failure;  heart failure with preserved ejection fraction;  NT-proBNP
DOI:
【DOI】10.16806/j.cnki.issn.1004-3934.2020.06.025
摘要:
目的 探讨H2FPEF评分N末端脑钠肽前体（NT-proBNP）对射血分数保留心力衰竭（HFpEF）患者预后评估的临床价值。方法 选取2018年1月至2018年12月安徽医科大学第三附属医院就诊的132例HFpEF患者作为研究对象，均予以H2FPEF评分和NT-proBNP检测。根据H2FPEF评分分为评分组（H2FPEF评分6分）和评分组（H2FPEF评分6分），规范治疗后随访1年，比较2组主要不良心血管事件（MACE）发生情况。应用单因素和多因素logistic回归模估计不良事件风险的几率和95％置信区间。应用受试者工作特征曲线（ROC）分析H2FPEF评分NT-proBNP评估不良预后的临床价值。结果 H2FPEF评分组MACE发生率（58.8%）于评分组（31.9%），P＜0.05；评分组心力衰竭再住院发生率（45.9%）于评分组（25.5%），P0.05；全因死亡和心血管死亡两者无显著差异，P0.05。多元Logistic回归分析结果显示：H2FPEF、LgNT-proBNP为HFpEF患者MACE发生的独立预测因子（OR 1.383，95% CI 1.186～1.782，P=0.022；OR 4.006，95% CI 3.217～5.622，P0.001）。ROC曲线分析显示：H2FPEF预测不良事件曲线下面积为0.712小于血浆NT-proBNP预测不良事件曲线下面积0.886。结论 H2FPEF评分NT-proBNP均可用于HFpEF患者的预后评估，但H2FPEF评分的预测能力可能不如NT-proBNP。
Abstract:
Objective To investigate the clinical value of H2FPEF score and NT-proBNP in evaluating the prognosis of heart failure patients with preserved ejection fraction(HFpEF). Methods One hundred and thirty-two patients with HFpEF were enrolled in the Third Affiliated Hospital of Anhui Medical University,from January 2018 to December 2018. The H2FPEF score and NT-proBNP test were conducted. According to the H2FPEF score,we divided the patients into the high score group (85 cases,H2FPEF≥6) and low score group(47 cases,H2FPEF＜6). All patients was Followed up for 1 year after standard treatment,and the incidence of major adverse cardiovascular events(MACE) was compared between the two groups. The odds ratio and 95% confidence intervals were estimated by univariate and multivariate logistic regression models for the risk of one-year adverse event. We use receiver operating characteristic curve(ROC) to compare the predictive value of H2FPEF score and NT-proBNP for poor prognosis. Results The incidence of MACE in the high score group(58.8%) was higher than that in the low score group(31.9%),P＜0.05.The incidence of heart failure rehospitalization in the high score group(45.9%) was higher than that in the low score group(25.5%),P＜0.05.There was no significant difference between all-cause death and cardiovascular death,P＞0.05. The multiple logistic regression analysis showed that H2FPEF and LgNT-proBNP were independent predictors of MACE in patients with HFpEF（OR 1.38395% CI 1.186～1.782P=0.022；OR 4.00695% CI 3.217～5.62P＜0.001）. ROC curve analysis showed that the area under the H2FPEF predicted adverse event curve(0.712)was smaller than the area under the plasma NT-proBNP predicted adverse event curve(0.886). Conclusion The H2FPEF score and NT-proBNP can be used for prognosis evaluation in patients with HFpEF,but the predictive power of the H2FPEF score is not as good as that of NT-proBNP.

参考文献/References:

[1] 中华医学会心血管病学分会心力衰竭学组中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志2018,46(10):760-789.
[2] 李琳莫卿莫婷等. 老年慢心力衰竭患者临床特征和药物治疗状况多中心回顾分析[J]. 中华医学杂志2018,98(9):673-677.
[3] 马里兰杨瑛陈章荣等. 中国西南地区心力衰竭发病情况回顾研究分析[J]. 中国全科医学2019,22(14):1678-1683.
[4] 陈宏周鹏侯霁芯等. 射血分数保留心力衰竭的临床特征预后因素分析[J]. 临床心血管病杂志2018,34(10):1018-1023.
[5] 罗威李绍持徐尚誉等. NT-ProBNP评估慢心力衰竭患者心功能的价值其影响因素的研究[J]. 中国循证心血管医学杂志2019,11(4):469-473.
[6] 亢扬富路. 心力衰竭患者血浆B利钠肽/氨基末端利钠肽原水平正常的研究进展[J]. 心血管病学进展2018,39(4):622-626.
[7] Reddy YNV,Carter RE,Obokata M,et al. A Simple,evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction[J]. Circulation,2018,138(9):861-870.
[8] WHO-Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies[J]. Lancet,2004,363(9403):157-163.
[9] Sueta D,Yamamoto E,Nishihara T,et al. H2FPEF Score as a prognostic value in HFpEF patients[J]. Am J Hypertens,2019,32(11):1082-1090.
[10] Salah K,Stienen S,Pinto YM,et al. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction[J]. Heart,2019,115(15):1182-1189.
[11] Savarese G,Orsini N,Hage C,et al. Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF,HFmrEF,and HFrEF[J]. JACC Heart Fail,2018,6(3):246-256.
[12] 曹娟,金雪娟,周俊,等. N末端B型利钠肽原对射血分数保留的心力衰竭患者全因死亡的预测价值[J]. 中华心血管病杂志, 2019, 47(11):875-881.
[13] Islam MN,Chowdhury MS,Paul GK,et al. Association of diastolic dysfunction with N-terminal pro-B-type natriuretic peptide level in heart failure patients with preserved ejection fraction[J]. Mymensingh Med J,2019,28(2):333-346.
[14] Draper J,Webb J,Jackson T,et al. Comparison of the diagnostic accuracy of plasma N-terminal pro-brain natriuretic peptide in patients ＜80 to those ＞80 years of age with heart failure[J]. Am J Cardiol,2018,122(12):2075-2079.
[15] Gergei I,Kr?mer BK,Scharnagl H,et al. Renal function,N-terminal pro-B-type natriuretic peptide,propeptide big-endothelin and patients with heart failure and preserved ejection fraction[J]. Peptides,2019,111(2):112-117.
[16] Buckley LF,Canada JM,Del Buono MG,et al. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction[J]. ESC Heart Fail,2018,5(2):372-378.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(6):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(6):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(6):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

更新日期/Last Update: 2020-09-22